SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc. -- FURX
GlobeNewswire - Wed May 14, 6:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
Synergy Pharma Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 10:00AM CDT
Synergy Pharma (SGYP) reported first quarter 2014 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
Business Wire - Tue May 13, 12:39PM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
Business Wire - Tue May 13, 12:34PM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest
PR Newswire - Tue May 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Novartis AG (NYSE: NVS), Cigna Corp. (NYSE: CI) and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2384-100free.
RiverVest Venture Partners' Portfolio Company Lumena is Sold to Shire for $260 million; Represents Sixth Exit from RiverVest Venture Fund II
Business Wire - Mon May 12, 9:39AM CDT
RiverVest Venture Partners today announced portfolio company Lumena Pharmaceuticals has been sold to Dublin-based Shire Plc., in a transaction with an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.
Pharma Stocks Technical Briefing -- Research on Forest Laboratories, Valeant Pharma, IntelliPharmaCeutics Intl., and Acura Pharma
PR Newswire - Thu May 08, 7:09AM CDT
On Wednesday, May 7, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. During the session, eight out of ten sectors ended on a positive note. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, with the index advancing 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) and Acura Pharmaceuticals Inc (NASDAQ: ACUR). Free technical research on FRX, VRX, IPCI and ACUR can be downloaded upon signing up at:
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Furiex Pharmaceuticals, Inc. in Connection with the Proposed Sale of the Company to Forest Laboratories, Inc.
Business Wire - Mon May 05, 3:41PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
Commit To Buy Forest Laboratories At $87.50, Earn 8.3% Annualized Using Options
at The Street - Mon May 05, 10:36AM CDT
Investors eyeing a purchase of Forest Laboratories, Inc. stock, but tentative about paying the going market price of $92.24/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Former Forest Laboratories GC Joins Lowenstein Sandler's Life Sciences Practice
PR Newswire - Mon May 05, 9:00AM CDT
Herschel S. Weinstein joined Lowenstein Sandler LLP today as Senior Counsel and Vice-Chair of its Life Sciences Group. Mr. Weinstein has more than 30 years of experience as in-house and outside counsel to the pharmaceutical industry. He most recently served as Senior Vice President and General Counsel at Forest Laboratories, the New York Stock Exchange listed specialty pharmaceutical company with more than $4 billion in annual revenue. Mr. Weinstein will be resident in Lowenstein's New York office.
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), WellPoint Inc. (NYSE: WLP), UnitedHealth Group Inc. (NYSE: UNH), Forest Laboratories Inc. (NYSE: FRX) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2020-100free.
Forest Laboratories, Inc. to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting
Business Wire - Fri May 02, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the American Psychiatric Association (APA) 167th annual meeting (May 3-7, 2014 in New York, N.Y.).
INVESTOR ALERT - FURIEX PHARMACEUTICALS, INC.: The Law Offices of Vincent Wong Investigates the Sale of Furiex Pharmaceuticals, Inc.
Business Wire - Fri May 02, 10:21AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) ("Furiex"
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]